🧬 Discussed at the Bioprocessing Summit Europe, the standards will help manufacturers and regulators address challenges in the fast-evolving cell therapy sector.
🔬 Experts will guide best practices in plasmid DNA and analyze adeno-associated virus production, enhancing innovation in this field.
Introduction:
The article discusses newly established standards by the U.S. Pharmacopeia (USP) aimed at improving the quality and consistency of manufacturing in the rapidly evolving field of gene therapy, particularly focusing on viral vectors.
- USP has introduced new standards for viral vector production, which will be discussed at the upcoming Bioprocessing Summit Europe.
- The standards are intended to aid both manufacturers and regulators in developing best practices to handle the complexities of biomanufacturing.
- Challenges include the variability in the quality of raw materials, such as plasmid DNA used in the therapy’s production.
- USP has consulted a panel of experts to formulate best practices for plasmid DNA, with formal adoption expected by February 2026.
- Future plans include addressing standards for other viral vectors, such as lentivirus and chimeric antigen receptor therapy (CAR T), to ensure the quality of innovative therapies.
Conclusion:
The introduction of new standards by USP is a significant step toward ensuring the quality and reliability of gene therapies, addressing the complexities of manufacturing. By establishing consensus best practices, USP aims to support both innovation within the pharmaceutical industry and regulatory oversight, ultimately benefiting patients through improved therapeutic options.
